Study S001356

Liraglutide: A Randomized, Double-blind, Placebo Controlled Trial to Assess Safety/Tolerability, Pharmacokinetics & Pharmacodynamics of Liraglutide in Pediatric (10-17 Years Old) With Type 2 Diabetes

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT00943501
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: DOUBLE
Status: COMPLETED
Enrollment: 21
Start: 2009-11
Primary completion: 2011-09
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: DRUG:liraglutide; DRUG:placebo
Results posted: FALSE
Secondary identifiers: OTHER:U1111-1111-9256; EUDRACT_NUMBER:2010-021057-39

Registered primary outcomes

Number and type of adverse events [up to 8 weeks]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0023675	Comparable liraglutide pharmacokinetics in pediatric and adult populations with type 2 diabetes: a population pharmacokinetic analysis. Petri KC, Clinical pharmacokinetics	2015	Other trial	PMID 25603819 DOI	cites ClinicalTrials.gov:NCT00943501; registry reference RESULT:25603819
R0026795	Liraglutide's safety, tolerability, pharmacokinetics, and pharmacodynamics in pediatric type 2 diabetes: a randomized, double-blind, placebo-controlled trial. Klein DJ, Diabetes technology & therapeutics	2014	Randomized trial	PMID 25036533 DOI	cites ClinicalTrials.gov:NCT00943501; registry reference RESULT:25036533